Recursion Pharmaceuticals Inc
RXRX5.090USD
-0.430-7.79%
Cierre 08/19, 16:00（ET）Cotizaciones retrasadas 15 min
2.20BCap. mercado
PérdidaP/E TTM
Más Datos de Recursion Pharmaceuticals Inc Compañía
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Información de la empresa
Símbolo de cotizaciónRXRX
Nombre de la empresaRecursion Pharmaceuticals Inc
Fecha de salida a bolsaApr 16, 2021
Director ejecutivoDr. Christopher Gibson, Ph.D.
Número de empleados840
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 16
Dirección41S Rio Grande Street
CiudadSALT LAKE CITY
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal84101
Teléfono13852690203
Sitio Webhttps://www.recursion.com/
Símbolo de cotizaciónRXRX
Fecha de salida a bolsaApr 16, 2021
Director ejecutivoDr. Christopher Gibson, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.20M
+0.06%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
135.82K
+2.20%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
55.91K
-60.78%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
Director, Chief Research and Development Officer, Chief Commercial Officer
Director, Chief Research and Development Officer, Chief Commercial Officer
14.63K
-20.60%
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.20M
+0.06%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
135.82K
+2.20%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
55.91K
-60.78%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
9.48M
63.99%
United Kingdom
5.34M
36.01%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 15 de ago
Actualizado: vie., 15 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
8.43%
ARK Investment Management LLC
7.72%
Baillie Gifford & Co.
5.66%
BlackRock Institutional Trust Company, N.A.
5.60%
SB Global Advisers Ltd
3.43%
Otro
69.16%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
8.43%
ARK Investment Management LLC
7.72%
Baillie Gifford & Co.
5.66%
BlackRock Institutional Trust Company, N.A.
5.60%
SB Global Advisers Ltd
3.43%
Otro
69.16%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
43.79%
Investment Advisor/Hedge Fund
10.49%
Venture Capital
7.26%
Sovereign Wealth Fund
3.78%
Individual Investor
2.94%
Hedge Fund
1.96%
Corporation
1.80%
Research Firm
1.73%
Bank and Trust
0.83%
Otro
25.42%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
658
317.16M
74.44%
-11.74M
2025Q1
665
322.62M
81.56%
-7.38M
2024Q4
611
317.29M
80.77%
+25.35M
2024Q3
560
281.65M
104.01%
-6.72M
2024Q2
527
272.94M
105.41%
+14.66M
2024Q1
478
234.97M
104.72%
-10.28M
2023Q4
433
227.80M
110.74%
+18.50M
2023Q3
402
195.18M
97.47%
+1.19M
2023Q2
358
172.49M
89.73%
-20.74M
2023Q1
345
171.25M
93.19%
-16.02M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
32.23M
8.06%
-1.74M
-5.12%
Mar 31, 2025
ARK Investment Management LLC
34.82M
8.71%
+2.47M
+7.63%
Mar 31, 2025
Baillie Gifford & Co.
24.39M
6.1%
-471.04K
-1.89%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.07M
5.02%
-234.35K
-1.15%
Mar 31, 2025
SB Global Advisers Ltd
14.67M
3.67%
--
--
Mar 31, 2025
Kinnevik AB
13.43M
3.36%
+1.53M
+12.84%
Mar 31, 2025
Mubadala Investment Company PJSC
12.99M
3.25%
--
--
Mar 31, 2025
State Street Global Advisors (US)
13.09M
3.27%
+506.90K
+4.03%
Mar 31, 2025
Novo Holdings A/S
9.67M
2.42%
-449.50K
-4.44%
Mar 31, 2025
MIC Capital Management UK LLP
9.64M
2.41%
-1.00
-0.00%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mié., 6 de ago
Actualizado: mié., 6 de ago
Nombre
Proporción
ARK Genomic Revolution ETF
5.68%
First Trust Nasdaq AI and Robotics ETF
2.38%
ARK Innovation ETF
1.41%
Franklin Genomic Advancements ETF
1.41%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
WisdomTree BioRevolution Fund
0.76%
AXS Green Alpha ETF
0.73%
SPDR S&P Biotech ETF
0.53%
WisdomTree Artificial Intelligence and Innov Fund
0.45%
Direxion Daily S&P Biotech Bull 3X Shares
0.34%
Ver más
ARK Genomic Revolution ETF
Proporción5.68%
First Trust Nasdaq AI and Robotics ETF
Proporción2.38%
ARK Innovation ETF
Proporción1.41%
Franklin Genomic Advancements ETF
Proporción1.41%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.88%
WisdomTree BioRevolution Fund
Proporción0.76%
AXS Green Alpha ETF
Proporción0.73%
SPDR S&P Biotech ETF
Proporción0.53%
WisdomTree Artificial Intelligence and Innov Fund
Proporción0.45%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.34%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
